Progression of atherosclerosis in ApoE-deficient mice that express distinct molecular forms of TNF-alpha

Journal of Pathology

Volumn 214, Issue 5, 2008, Pages 574-583

  Canault, M ^a,b   Peiretti, F ^a,b   Poggi, M ^a,b   Mueller, C ^c   Kopp, F ^b   Bonardo, B ^a,b   Bastelica, D ^a,b   Nicolay, A ^b   Alessi, M C ^a,b   Nalbone, G ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Atherosclerosis; Gene targeting; Inflammation; Mouse; TNF; Transmembrane TNF

Indexed keywords

ACTIN; APOLIPOPROTEIN E; COLLAGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; AORTIC DISEASES; AORTIC VALVE; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; CHOLESTEROL; DIET, ATHEROGENIC; DISEASE PROGRESSION; GENE EXPRESSION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41649110221     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2305     Document Type: Article

References (60)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
2. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302.
3. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991;89:247- 254.
4. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gok H, et al. Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 1993;44:332-337.
5. Bruunsgaard H, Skinhoj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000;121:255-260.
6. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-{alpha} and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-2153.
7. Skoog T, Dichtl W, Boquist S, Skoglund-Andersson C, Karpe F, Tang R, et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002;23:376-383.
8. Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S, et al. Exclusive expression of transmembrane TNF-[alpha] in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 2004;172:211-218.
9. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-{alpha} reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2004;24:2137-2142.
10. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. Disruption of tumor necrosis factor-[alpha] gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005;180:11-17.
11. Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP, Havekes LM, et al. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res 2005;66:179-185.
12. Elhage R, Maret A, Pieraggi M-T, Thiers JC, Arnal JF, Bayard F. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation 1998;97:242-244.
13. Eissner G, Kolch W, Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004;15:353-366.
14. MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002;135:855-875.
15. Mueller C, Corazza N, Trachsel-Loseth S, Eugster H-P, Buhler-Jungo M, Brunner T, et al. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J Biol Chem 1999;274:38112- 38118.
16. Ruuls SR, Hoek RM, Ngo VN, McNeil T, Lucian LA, Janatpour MJ, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001;15:533-543.
17. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, et al. Innate and acquired immunity in atherogenesis. Nature Med 2002;8:1218-1226.
18. Hansson GK, Libby P, Schonbeck U, Yan Z-Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
19. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86:515-581.
20. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
21. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-736.
22. Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi M-F, Coudeyre J-C, et al. The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis 2006;187:82-91.
23. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Characterization of tumor necrosis factor-deficient mice. PNAS 1997;94:8093-8098.
24. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979;11:447-455.
25. Alessi M-C, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268.
26. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109:745-753.
27. Buono C, Lichtman AH. Co-stimulation and plaque-antigen-specific T-cell responses in atherosclerosis. Trends Cardiovasc Med 2004;14:166- 172.
28. Binder CJ, Hartvigsen K, Chang M-K, Miller M, Broide D, Palinski W, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004;114:427-437.
29. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F, et al. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation 2003;108:1232-1237.
30. Ait-Oufella H, Salomon BL, Potteaux S, Robertson A-KL, Gourdy P, Zoll J, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nature Med 2006;12:178-180.
31. Leeuwenberg J, Dentener M, Buurman W. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol 1994;152:5070-5076.
32. King VL, Szilvassy SJ Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor -/- mice. Arterioscler Thromb Vasc Biol 2002;22:456-461.
33. VanderLaan PA, Reardon CA Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004;24:12-22.
34. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005;112:870-878.
35. Dibbs ZI, Diwan A, Nemoto S, DeFreitas G, Abdellatif M, Carabello BA, et al. Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation 2003;108:1002-1008.
36. Olleros ML, Guler R, Corazza N, Vesin D, Eugster H-P, Marchai G, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-{alpha}. J Immunol 2002;168:3394-3401.
37. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990;63:251-258.
38. Ferran C, Dautry F, Merite S, Sheehan K, Schreiber R, Grau G, et al. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994;93:2189-2196.
39. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83:793- 802.
40. Parry SL, Sebbag M, Feldmann M, Brennan FM. Contact with T cells modulates monocyte IL-10 production: role of T cell membrane TNF-alpha. J Immunol 1997;158:3673-3681.
41. Marra LE, Zhang ZX, Joe B, Campbell J, Levy GA, Penninger J, et al. IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-{alpha}. J Immunol 2004;172:1028-1035.
42. Harashima S-I, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, et al. Outside-to-inside signal through the membrane TNF-{alpha} induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 2001;166:130-136.
43. Kober F, Canault M, Peiretti F, Mueller C, Kopp F, Alessi M-C, et al. MRI follow-up of TNF-dependent differential progression of atherosclerotic wall-thickening in mouse aortic arch from early to advanced stages. Atherosclerosis 2007;195:e93-99. Epub 2007 July 30.
44. Schreyer SA, Vick CM, Le Boeuf RC. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem 2002;277:12364-12368.
45. George J, Yacov N, Breitbart E, Bangio L, Shaish A, Gilburd B, et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with [beta]2-glycoprotein I. Cardiovasc Res 2004;62:603-609.
46. van Puijvelde GHM, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJC, van der Zee R, et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006;114:1968-1976.
47. Hsu HY, Twu YC. Tumor necrosis factor-alpha-mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage. J Biol Chem 2000;275:41035-41048.
48. de Boer OJ, van der Wal AC, Verhagen CE, Becker AE. Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques. J Pathol 1999;188:174-179.
49. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, et al. Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: protective and deleterious effects. Immunity 2005;22:93-104.
50. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993;177:1575-1585.
51. Vudattu NK, Holler E, Ewing P, Schulz U, Haffner S, Burger V, et al. Reverse signalling of membrane-integrated tumour necrosis factor differentially regulates alloresponses of CD4+ and CD8+ T cells against human microvascular endothelial cells. Immunology 2005;115:536-543.
52. Rossol M, Meusch U, Pierer M, Kaltenhauser S, Hantzschel H, Hauschildt S, et al. Interaction between transmembrane TNF and TNFR1/2 mediates the activation of monocytes by contact with T cells. J Immunol 2007;179:4239-4248.
53. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P, et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nature Med 2007;13:719-724.
54. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nature Immunol 2005;6:331-337.
55. Chen X, Baumel M, Mannel DN, Howard OMZ, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4 4- CD25+ T regulatory cells. J Immunol 2007;179:154-161.
56. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2007;2:e779.
57. Hegyi L, Skepper JN, Cary NR, Mitchinson MJ. Foam cell apoptosis and the development of the lipid core of human atherosclerosis. J Pathol 1996;180:423-429.
58. Corazza N, Brunner T, Buri C, Rihs S, Imboden MA, Seibold I, et al. Transmembrane tumor necrosis factor is a potent inducer of colitis even in the absence of its secreted form. Gastroenterology 2004;127:816-825.
59. Watts AD, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD, et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J 1999;18:2119-2126.
60. Canault M, Peiretti F, Mueller C, Deprez P, Bonardo B, Bernot D, et al. Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non-cleavable form of TNFalpha. Effect on tumor necrosis factor alpha receptor type 2. Thromb Haemost 2004;92:1428-1437.